Table 3 Associations of ferritin levels in SVR patients at 24 weeks posttherapy.

From: Evolution of ferritin levels in hepatitis C patients treated with antivirals

24-week post-therapy factors

Univariate analyses

Multivariate analyses

95% CI of OR (OR)

p values

95% CI of OR (OR)

p values

Male, yes

− 47.83 ~ 132.4 (42.29)

0.357

  

Age, (years)

− 1.49 ~ 5.71 (2.1)

0.251

  

BMI (kg/m2)

− 16.7 ~ 7.286 (− 4.7)

0.44

  

ALT (U/L)

6.19 ~ 11.91 (9.052)

< 0.001

3.007 ~ 8.107 (5.557)

< 0.001

eGFR (mL/min/1.73 m2)

− 4.526 ~ − 1.821 (− 3.17)

< 0.001

− 3.9 ~ − 1.61 (− 2.76)

< 0.001

TG (mg/dL)

0.331 ~ 1.228 (0.779)

0.001

0.146 ~ 0.909 (0.527)

0.017

TC (mg/dL)

0.956 ~ 3.423 (2.189)

0.001

0.211 ~ 2.346 (1.278)

0.019

HOMA-IR

− 0.689 ~ 29.63 (14.47)

0.061

− 5.03 ~ 20.09 (7.53)

0.239

Uric acid (mg/dL)

33.59 ~ 91.36 (62.474)

< 0.001

− 7.11 ~ 40.52 (16.70)

0.169

Fe/TIBC (%)

1811 ~ 2338 (2075)

< 0.001

1521 ~ 2030 (1776)

< 0.001

Hb (g/dL)

− 34.76 ~ 18.93 (− 7.91)

0.563

  

NLR

− 34.1 ~ 66.98 (16.45)

0.523

  

Platelet (103/μL)

− 2.06 ~ − 0.591 (− 1.29)

0.001

− 1.12 ~ 0.661 (− 0.234)

0.608

Steatosis, yes

− 177.8 ~ 86.3 (− 45)

0.495

  

Liver cirrhosis, yes

− 77.0 ~ 256.8 (89.92)

0.29

  

Fibrosis-4 index

− 2.56 ~ 42.1 (19.755)

0.083

− 4.36 ~ 47.8 (21.72)

0.102

IFNL3-rs12979860

CC genotype, yes

− 189.3 ~ 80.9 (− 54.2)

0.431

  

Therapy (interferon = 1, DAA = 2)

− 352 ~ − 170 (− 261)

< 0.001

− 331 ~ − 161 (− 246)

< 0.001

  1. OR odds ratio, BMI body mass index, ALT alanine transaminase, eGFR estimated glomerular filtration rate, TG triglycerides, TC total cholesterol, HOMA-IR homeostatic model assessment for insulin resistance, Fe/TIBC serum Iron/total iron binding capacity, Hb hemoglobin, NLR neutrophil lymphocyte ratio, FIB-4 fibrosis-4, IFNL3 interferon-λ3, DAA direct-acting antivirals.
Back to article page